Clinical Trial Detail

NCT ID NCT02092324
Title Ruxolitinib Phosphate in Treating Patients With Chronic Neutrophilic Leukemia or Atypical Chronic Myeloid Leukemia
Recruitment Completed
Gender both
Phase Phase II
Variant Requirements No
Sponsors OHSU Knight Cancer Institute
Indications

chronic neutrophilic leukemia

chronic myeloid leukemia

Therapies

Ruxolitinib

Age Groups: adult senior

No variant requirements are available.